Bicara Therapeutics (NASDAQ:BCAX) Releases Quarterly Earnings Results, Beats Expectations By $0.04 EPS

Bicara Therapeutics (NASDAQ:BCAX) announced its quarterly earnings results on Monday. The company reported ($0.68) earnings per share for the quarter, topping the consensus estimate of ($0.72) by $0.04, FiscalAI reports.

Here are the key takeaways from Bicara Therapeutics’ conference call:

• Management announced that ficerafusp alfa in combination with pembrolizumab received Breakthrough Therapy Designation for first‑line metastatic/unresectable HPV‑negative head and neck cancer, signaling potential regulatory acceleration.
• Bicara selected 1,500 mg weekly as the optimal biological dose and has advanced into the phase III FORTIFY‑HN01 pivotal study with a planned interim analysis in mid‑2027 toward a possible accelerated approval strategy.
• Management highlighted Phase Ib data across ~90 patients showing deep, durable responses—reported median duration of response of 21.7 months and median overall survival of 21.3 months—which they position as a key clinical differentiator for HPV‑negative disease.
• The company completed an oversubscribed public offering (net proceeds ~$161.8M) and entered 2026 with $414.8M, stating a cash runway into the first half of 2029 to fund the pivotal program, alternative dosing study, manufacturing, and pre‑launch activities.
• Bicara cautioned that operating expenses rose in 2025 and are expected to increase further in 2026 as it ramps clinical operations, manufacturing and early commercial/medical build, implying higher near‑term cash burn despite the recent financing.

Bicara Therapeutics Stock Up 4.5%

NASDAQ:BCAX opened at $19.89 on Wednesday. The stock has a market capitalization of $1.09 billion, a price-to-earnings ratio of -7.86 and a beta of -0.78. Bicara Therapeutics has a 52 week low of $7.80 and a 52 week high of $20.25. The firm has a 50 day moving average of $17.21 and a 200 day moving average of $16.67.

More Bicara Therapeutics News

Here are the key news stories impacting Bicara Therapeutics this week:

• Positive Sentiment: Bicara selected 1,500 mg weekly as the optimal ficerafusp alfa dose, formally initiated the pivotal Phase 3 FORTIFI‑HN01 trial and said an interim analysis is expected mid‑2027; the company also reported work on a less‑frequent dosing regimen — a clear near‑term clinical catalyst. Bicara Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
• Positive Sentiment: Phase‑1/1b efficacy (12‑month OS 61%, confirmed ORR 54% with ficerafusp alfa + KEYTRUDA) supports continued development and attracted a maintained “Buy” view in coverage notes citing the Phase‑3 advancement. Bicara: Maintaining ‘Buy’ Rating On Ficerafusp Alfa Phase 3 Advancement
• Positive Sentiment: Multiple bullish firms reaffirmed or raised targets: HC Wainwright raised its PT to $42 (buy), Wedbush kept an outperform with $30 PT and Citizens/JMP kept market‑outperform with $31 — these high targets support upside narratives among growth/biotech investors. Benzinga Coverage of Analyst Actions
• Positive Sentiment: Q4 2025 results: Bicara beat consensus EPS (reported $(0.68) vs. $(0.72) est.) and reiterated business plans on the earnings call; company presentations highlighted cash runway and development milestones — financial stability reduces near‑term financing risk. Bicara Therapeutics Inc (BCAX) Q4 2025 Earnings Call Highlights
• Neutral Sentiment: Insider activity: CEO Claire Mazumdar sold ~8,234 shares (~$154k) in early March, representing a small percentage of her holdings — notable but not large enough to signal a decisive vote of no confidence. Bicara Therapeutics CEO Sold Over 8,000 Company Shares
• Negative Sentiment: Mixed analyst signals: Goldman Sachs and Wells Fargo raised price targets to $16 but assigned neutral/equal‑weight ratings; both $16 targets sit well below the current market price and could pressure sentiment among institutional investors focused on short‑term valuation. Goldman Sachs Raises Price Target Benzinga: Wells Fargo Action

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the company. UBS Group restated a “buy” rating on shares of Bicara Therapeutics in a report on Wednesday, January 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Bicara Therapeutics in a report on Friday, January 9th. Wells Fargo & Company upped their price objective on Bicara Therapeutics from $11.00 to $16.00 and gave the stock an “equal weight” rating in a research note on Tuesday. Citizens Jmp reaffirmed a “market outperform” rating and set a $31.00 price objective on shares of Bicara Therapeutics in a research report on Tuesday. Finally, The Goldman Sachs Group lifted their target price on Bicara Therapeutics from $14.00 to $16.00 and gave the company a “neutral” rating in a research note on Tuesday. Eight investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $28.00.

Insider Activity

In other news, insider David Raben sold 16,300 shares of the company’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $18.52, for a total transaction of $301,876.00. Following the transaction, the insider directly owned 55,286 shares of the company’s stock, valued at approximately $1,023,896.72. This represents a 22.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Ryan Cohlhepp sold 17,392 shares of the firm’s stock in a transaction on Tuesday, March 3rd. The stock was sold at an average price of $18.16, for a total value of $315,838.72. Following the completion of the sale, the chief operating officer directly owned 205,141 shares of the company’s stock, valued at $3,725,360.56. The trade was a 7.82% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 137,969 shares of company stock valued at $2,586,198 over the last three months.

Institutional Investors Weigh In On Bicara Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. Legal & General Group Plc grew its stake in shares of Bicara Therapeutics by 64.1% during the second quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock worth $29,000 after acquiring an additional 1,233 shares during the last quarter. Larson Financial Group LLC raised its position in shares of Bicara Therapeutics by 1,015.5% in the 3rd quarter. Larson Financial Group LLC now owns 3,949 shares of the company’s stock valued at $62,000 after purchasing an additional 3,595 shares during the last quarter. Tower Research Capital LLC TRC boosted its stake in Bicara Therapeutics by 419.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company’s stock worth $44,000 after purchasing an additional 3,866 shares in the last quarter. New York State Common Retirement Fund boosted its stake in Bicara Therapeutics by 87.5% in the 4th quarter. New York State Common Retirement Fund now owns 7,500 shares of the company’s stock worth $126,000 after purchasing an additional 3,500 shares in the last quarter. Finally, Creative Planning purchased a new stake in Bicara Therapeutics during the 3rd quarter worth approximately $159,000.

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.